New targets and therapies for gastrointestinal stromal tumors (Q47432725)

16 January 2018

title

New targets and therapies for gastrointestinal stromal tumors (English)

1 reference

16 January 2018

author

Agnieszka Wozniak

series ordinal

1

1 reference

16 January 2018

Maria Debiec-Rychter

series ordinal

3

object named as

Maria Debiec-Rychter

1 reference

16 January 2018

4

Patrick Schöffski

1 reference

16 January 2018

author name string

Yemarshet K Gebreyohannes

series ordinal

2

1 reference

16 January 2018

publication date

7 November 2017

1 reference

16 January 2018

Expert Review of Anticancer Therapy

published in

1 reference

16 January 2018

volume

17

1 reference

16 January 2018

issue

12

1 reference

16 January 2018

page(s)

1117-1129

1 reference

16 January 2018

Gastrointestinal stromal tumour

cites work

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

GIST under imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Expression of the receptor for type i insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Integrin-regulated FAK-Src signaling in normal and cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Imatinib Upregulates Compensatory Integrin Signaling in a Mouse Model of Gastrointestinal Stromal Tumor and Is More Effective When Combined with Dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Molecular targets for tumour progression in gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Evolutionary dynamics of cancer in response to targeted combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

No KRAS mutations found in gastrointestinal stromal tumors (GISTs): molecular genetic study of 514 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

BRAF mutation status in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Inhibition of HSP90 molecular chaperones: moving into the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

New and emerging HDAC inhibitors for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Cell cycle proteins as promising targets in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

PDL1 expression is an independent prognostic factor in localized GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

Current status of immunotherapy for gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/14737140.2017.1400386

10.1080/14737140.2017.1400386

21 January 2018

Identifiers

DOI

1 reference

16 January 2018

1 reference

16 January 2018